Peanut Allergy Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (Antihistamines, Epinephrine, Immunotherapies, Others), By Route of Administration (Oral, Intravenous, Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Region & Competition, 2021-2031F
The global market for peanut allergy treatments is projected to expand significantly, rising from USD 616.29 million in 2025 to USD 1330.82 million by 2031, demonstrating a compound annual growth rate of 13.69%. This market encompasses pharmaceutical products and immunotherapies, including oral and epicutaneous treatments, designed to desensitize individuals to peanut allergens and reduce the likelihood of severe anaphylactic responses.
Key growth factors for this market are the increasing worldwide incidence of IgE-mediated food allergies and considerable financial backing for clinical research and development programs focused on achieving long-term tolerance in both children and adults. Illustrating this dedication, the National Peanut Board reported an investment of over $38 million in 2025, specifically allocated to food allergy research and outreach efforts.
Market Driver
A primary driver for the global peanut allergy treatment market is the escalating number of regulatory approvals for innovative therapeutics, which is significantly broadening patient eligibility and geographical access. Regulatory authorities are increasingly endorsing oral and epicutaneous immunotherapies, thereby paving the way for products aimed at younger patient groups where early intervention is crucial.
This trend enables manufacturers to address a critical unmet need in pediatric populations, who were previously confined to allergy avoidance strategies. For example, in January 2025, Stallergenes Greer announced European Commission approval for Palforzia's use in toddlers aged 1 to 3 with a confirmed diagnosis, expanding the market and stimulating further advancements in desensitization techniques.
Market Challenge
The global peanut allergy treatment market's expansion is notably limited by the safety concerns inherent in current immunotherapy protocols, particularly the possibility of anaphylaxis induced by treatment. These risks demand strict Risk Evaluation and Mitigation Strategies, requiring extended medical oversight during the initial phases of dose escalation.
This requirement places a considerable logistical strain on healthcare providers, as clinics must allocate specialized personnel and resources to monitor patients for severe reactions post-administration. This consequently creates a bottleneck in patient flow, restricting the number of individuals who can receive treatment concurrently and largely confining access to medical centers with ample resources.
Market Trends
A significant trend is the advancement of non-invasive epicutaneous immunotherapy patches, which involves substantial capital investment in late-stage clinical trials to confirm safety profiles distinct from systemic oral formulations. These patches utilize the skin's immune mechanisms to induce tolerance, differing from oral regimens that require ingestion, leading developers to maintain high operational expenditures to complete regulatory submissions.
The rigorous nature of this development phase is reflected in the financial reports of key patch developers; DBV Technologies, for instance, reported a net loss of $102.1 million in the third quarter of 2025, illustrating the considerable resources committed to progressing its Viaskin Peanut program through crucial testing stages.
Key Market Players
In this report, the Global Peanut Allergy Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Peanut Allergy Treatment Market.
Available Customizations:
Global Peanut Allergy Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Key growth factors for this market are the increasing worldwide incidence of IgE-mediated food allergies and considerable financial backing for clinical research and development programs focused on achieving long-term tolerance in both children and adults. Illustrating this dedication, the National Peanut Board reported an investment of over $38 million in 2025, specifically allocated to food allergy research and outreach efforts.
Market Driver
A primary driver for the global peanut allergy treatment market is the escalating number of regulatory approvals for innovative therapeutics, which is significantly broadening patient eligibility and geographical access. Regulatory authorities are increasingly endorsing oral and epicutaneous immunotherapies, thereby paving the way for products aimed at younger patient groups where early intervention is crucial.
This trend enables manufacturers to address a critical unmet need in pediatric populations, who were previously confined to allergy avoidance strategies. For example, in January 2025, Stallergenes Greer announced European Commission approval for Palforzia's use in toddlers aged 1 to 3 with a confirmed diagnosis, expanding the market and stimulating further advancements in desensitization techniques.
Market Challenge
The global peanut allergy treatment market's expansion is notably limited by the safety concerns inherent in current immunotherapy protocols, particularly the possibility of anaphylaxis induced by treatment. These risks demand strict Risk Evaluation and Mitigation Strategies, requiring extended medical oversight during the initial phases of dose escalation.
This requirement places a considerable logistical strain on healthcare providers, as clinics must allocate specialized personnel and resources to monitor patients for severe reactions post-administration. This consequently creates a bottleneck in patient flow, restricting the number of individuals who can receive treatment concurrently and largely confining access to medical centers with ample resources.
Market Trends
A significant trend is the advancement of non-invasive epicutaneous immunotherapy patches, which involves substantial capital investment in late-stage clinical trials to confirm safety profiles distinct from systemic oral formulations. These patches utilize the skin's immune mechanisms to induce tolerance, differing from oral regimens that require ingestion, leading developers to maintain high operational expenditures to complete regulatory submissions.
The rigorous nature of this development phase is reflected in the financial reports of key patch developers; DBV Technologies, for instance, reported a net loss of $102.1 million in the third quarter of 2025, illustrating the considerable resources committed to progressing its Viaskin Peanut program through crucial testing stages.
Key Market Players
- Vedanta Biosciences, Inc.
- Alladapt Immunotherapeutics, Inc.
- Regeneron Pharmaceuticals Inc.
- Aravax Pty Ltd
- Teva Pharmaceutical Industries Limited
- Prota Therapeutics Pty Ltd.
- Aimmune Therapeutics, Inc.
- DBV Technologies SA
- Sanofi SA
- Mylan N.V.
In this report, the Global Peanut Allergy Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Peanut Allergy Treatment Market, By Drug Class
- Antihistamines
- Epinephrine
- Immunotherapies
- Others
- Peanut Allergy Treatment Market, By Route of Administration
- Oral
- Intravenous
- Others
- Peanut Allergy Treatment Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Peanut Allergy Treatment Market, By Region
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Peanut Allergy Treatment Market.
Available Customizations:
Global Peanut Allergy Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL PEANUT ALLERGY TREATMENT MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class (Antihistamines, Epinephrine, Immunotherapies, Others)
5.2.2. By Route of Administration (Oral, Intravenous, Others)
5.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
5.2.4. By Region
5.2.5. By Company (2025)
5.3. Market Map
6. NORTH AMERICA PEANUT ALLERGY TREATMENT MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class
6.2.2. By Route of Administration
6.2.3. By Distribution Channel
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Peanut Allergy Treatment Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Class
6.3.1.2.2. By Route of Administration
6.3.1.2.3. By Distribution Channel
6.3.2. Canada Peanut Allergy Treatment Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Class
6.3.2.2.2. By Route of Administration
6.3.2.2.3. By Distribution Channel
6.3.3. Mexico Peanut Allergy Treatment Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Class
6.3.3.2.2. By Route of Administration
6.3.3.2.3. By Distribution Channel
7. EUROPE PEANUT ALLERGY TREATMENT MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Route of Administration
7.2.3. By Distribution Channel
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Peanut Allergy Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Route of Administration
7.3.1.2.3. By Distribution Channel
7.3.2. France Peanut Allergy Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Route of Administration
7.3.2.2.3. By Distribution Channel
7.3.3. United Kingdom Peanut Allergy Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Route of Administration
7.3.3.2.3. By Distribution Channel
7.3.4. Italy Peanut Allergy Treatment Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Class
7.3.4.2.2. By Route of Administration
7.3.4.2.3. By Distribution Channel
7.3.5. Spain Peanut Allergy Treatment Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Class
7.3.5.2.2. By Route of Administration
7.3.5.2.3. By Distribution Channel
8. ASIA PACIFIC PEANUT ALLERGY TREATMENT MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Route of Administration
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Peanut Allergy Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Route of Administration
8.3.1.2.3. By Distribution Channel
8.3.2. India Peanut Allergy Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Route of Administration
8.3.2.2.3. By Distribution Channel
8.3.3. Japan Peanut Allergy Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Route of Administration
8.3.3.2.3. By Distribution Channel
8.3.4. South Korea Peanut Allergy Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Class
8.3.4.2.2. By Route of Administration
8.3.4.2.3. By Distribution Channel
8.3.5. Australia Peanut Allergy Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Class
8.3.5.2.2. By Route of Administration
8.3.5.2.3. By Distribution Channel
9. MIDDLE EAST & AFRICA PEANUT ALLERGY TREATMENT MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Route of Administration
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Peanut Allergy Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Route of Administration
9.3.1.2.3. By Distribution Channel
9.3.2. UAE Peanut Allergy Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Route of Administration
9.3.2.2.3. By Distribution Channel
9.3.3. South Africa Peanut Allergy Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Route of Administration
9.3.3.2.3. By Distribution Channel
10. SOUTH AMERICA PEANUT ALLERGY TREATMENT MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Class
10.2.2. By Route of Administration
10.2.3. By Distribution Channel
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Peanut Allergy Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Class
10.3.1.2.2. By Route of Administration
10.3.1.2.3. By Distribution Channel
10.3.2. Colombia Peanut Allergy Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Class
10.3.2.2.2. By Route of Administration
10.3.2.2.3. By Distribution Channel
10.3.3. Argentina Peanut Allergy Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Class
10.3.3.2.2. By Route of Administration
10.3.3.2.3. By Distribution Channel
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL PEANUT ALLERGY TREATMENT MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Vedanta Biosciences, Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Alladapt Immunotherapeutics, Inc.
15.3. Regeneron Pharmaceuticals Inc.
15.4. Aravax Pty Ltd
15.5. Teva Pharmaceutical Industries Limited
15.6. Prota Therapeutics Pty Ltd.
15.7. Aimmune Therapeutics, Inc.
15.8. DBV Technologies SA
15.9. Sanofi SA
15.10. Mylan N.V.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL PEANUT ALLERGY TREATMENT MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class (Antihistamines, Epinephrine, Immunotherapies, Others)
5.2.2. By Route of Administration (Oral, Intravenous, Others)
5.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
5.2.4. By Region
5.2.5. By Company (2025)
5.3. Market Map
6. NORTH AMERICA PEANUT ALLERGY TREATMENT MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class
6.2.2. By Route of Administration
6.2.3. By Distribution Channel
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Peanut Allergy Treatment Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Class
6.3.1.2.2. By Route of Administration
6.3.1.2.3. By Distribution Channel
6.3.2. Canada Peanut Allergy Treatment Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Class
6.3.2.2.2. By Route of Administration
6.3.2.2.3. By Distribution Channel
6.3.3. Mexico Peanut Allergy Treatment Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Class
6.3.3.2.2. By Route of Administration
6.3.3.2.3. By Distribution Channel
7. EUROPE PEANUT ALLERGY TREATMENT MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Route of Administration
7.2.3. By Distribution Channel
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Peanut Allergy Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Route of Administration
7.3.1.2.3. By Distribution Channel
7.3.2. France Peanut Allergy Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Route of Administration
7.3.2.2.3. By Distribution Channel
7.3.3. United Kingdom Peanut Allergy Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Route of Administration
7.3.3.2.3. By Distribution Channel
7.3.4. Italy Peanut Allergy Treatment Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Class
7.3.4.2.2. By Route of Administration
7.3.4.2.3. By Distribution Channel
7.3.5. Spain Peanut Allergy Treatment Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Class
7.3.5.2.2. By Route of Administration
7.3.5.2.3. By Distribution Channel
8. ASIA PACIFIC PEANUT ALLERGY TREATMENT MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Route of Administration
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Peanut Allergy Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Route of Administration
8.3.1.2.3. By Distribution Channel
8.3.2. India Peanut Allergy Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Route of Administration
8.3.2.2.3. By Distribution Channel
8.3.3. Japan Peanut Allergy Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Route of Administration
8.3.3.2.3. By Distribution Channel
8.3.4. South Korea Peanut Allergy Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Class
8.3.4.2.2. By Route of Administration
8.3.4.2.3. By Distribution Channel
8.3.5. Australia Peanut Allergy Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Class
8.3.5.2.2. By Route of Administration
8.3.5.2.3. By Distribution Channel
9. MIDDLE EAST & AFRICA PEANUT ALLERGY TREATMENT MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Route of Administration
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Peanut Allergy Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Route of Administration
9.3.1.2.3. By Distribution Channel
9.3.2. UAE Peanut Allergy Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Route of Administration
9.3.2.2.3. By Distribution Channel
9.3.3. South Africa Peanut Allergy Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Route of Administration
9.3.3.2.3. By Distribution Channel
10. SOUTH AMERICA PEANUT ALLERGY TREATMENT MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Class
10.2.2. By Route of Administration
10.2.3. By Distribution Channel
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Peanut Allergy Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Class
10.3.1.2.2. By Route of Administration
10.3.1.2.3. By Distribution Channel
10.3.2. Colombia Peanut Allergy Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Class
10.3.2.2.2. By Route of Administration
10.3.2.2.3. By Distribution Channel
10.3.3. Argentina Peanut Allergy Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Class
10.3.3.2.2. By Route of Administration
10.3.3.2.3. By Distribution Channel
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL PEANUT ALLERGY TREATMENT MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Vedanta Biosciences, Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Alladapt Immunotherapeutics, Inc.
15.3. Regeneron Pharmaceuticals Inc.
15.4. Aravax Pty Ltd
15.5. Teva Pharmaceutical Industries Limited
15.6. Prota Therapeutics Pty Ltd.
15.7. Aimmune Therapeutics, Inc.
15.8. DBV Technologies SA
15.9. Sanofi SA
15.10. Mylan N.V.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
